Vaxil Bio Ltd (PK) (VXLLF)

VXLLF: effective May 15,2015 a one for 50 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Halted pending News

I more than doubled my holdings today. It is not that much, but I believe that the company is heading in the right direction. I will look to buy more if I am right.

Gary

VXLLF up 138 % today and VXL:TSX-V up 33% and 1.5 mill volume on VXL

Anyone know what is happening here today?

Gary

Now it's over a year since the last post. Anyone know of anything happening at the company.

Gary

About 50 weeks since the last post here, this site sure went dead.

Stock proposed for 10:1 reverse split...........not liking it.


HA

New video out:

Vaxil Bio; Explaining the Meaning of the Covid 19 Challenge Study and Answering Questions

Thanks,

I think the potential here is great enough that I'm intending to hold on regardless of such setbacks. I don't think this is the only product they're working on, but frankly know little about the company.

Gary

Vaxil just released an update and it wasn't all positive.

https://vaxil-bio.com/vaxil-provides-strategy-update-from-conclusion-of-covid-19-challenge-study/


But the admin from our Discord group comes to another conclusion:

Ok so...what happened earlier from everything I've gathered....someone on the cad side dumped 300k shares at open...1 of 2 reasons a leak, or someone mad they didn't get news and said fuxk it, that cause all the retail to dump like crazy after seeing -20%....then a whale scooped them all up at -70% and brought it back up to .44, a circuit breaker was triggered due to the offer trading. Which inreturn caused the halt. They did and still are investigating a leak, probably will go nowhere. Now as for the news release! Spoke with people (not saying who anymore, after all the threats), they could have and should have worded it better. Its not as bad as it seems. Some mice actually lived, most died suddenly in the end, the u.s army and both vaxil.were actually quite pleased with the first trial. They all.believe it's a simple dosage mistake. The oral also seems more promising once they figure out the links. This is nowhere near over and the signal peptide method will be proven once they get the kinks right. Alot of buzz from big pharmas who saw this news and actually was still pleased...soo calm down people. Sucks balls...how sp was decimated! Unreal the sell offf
Just know this will be back and very soon with news and better than ever, I just know it
Now as for this discord..end of week have to pick something else...if not tomorrow.. vaxil will take a week or so to get back on track

Anyone know what happened today when the bottom fell out.

Thanks,

Gary

.....and every year from now on the 3rd Tuesday of February will be know as "Peptide Tuesday"....or has that already been done?

The next NR by VXL will be somewhat of a game changer. It won't be the classic rise in SP then a pull back to a higher base, it will run. The next NR , if positive sets a whole new playing field, puts VXL in another league of its own

The Targeting Unmutatable Targets Bandwagon

https://www.nature.com/articles/d41586-021-00367-7

Excerpt

"So when laboratory tests showed that the 501Y.V2 variant identified in South Africa (also called B.1.351) is partially resistant to antibodies raised against previous coronavirus variants, researchers wondered whether T cells could be less vulnerable to its mutations.

Early results suggest that this might be the case. In a preprint published on 9 February, researchers found that most T-cell responses to coronavirus vaccination or previous infection do not target regions that were mutated in two recently discovered variants, including 501Y.V22. Sette says that his group also has preliminary evidence that the vast majority of T-cell responses are unlikely to be affected by the mutations."


No Vaxil mention but Gritstone is pointed out. With a ~$700 million valuation the do seem to have a bit more . . . traction than Vaxil.

Maybe if clinical trials on the horizon for Vaxil that'll help close the valuation gap.

https://vaxil-bio.com/vaxil-appoints-a-special-advisor-to-the-board-of-directors/

The Targeting Unmutatable Targets Bandwagon

https://www.nature.com/articles/d41586-021-00367-7

Excerpt

"So when laboratory tests showed that the 501Y.V2 variant identified in South Africa (also called B.1.351) is partially resistant to antibodies raised against previous coronavirus variants, researchers wondered whether T cells could be less vulnerable to its mutations.

Early results suggest that this might be the case. In a preprint published on 9 February, researchers found that most T-cell responses to coronavirus vaccination or previous infection do not target regions that were mutated in two recently discovered variants, including 501Y.V22. Sette says that his group also has preliminary evidence that the vast majority of T-cell responses are unlikely to be affected by the mutations."


No Vaxil mention but Gritstone is pointed out. With a ~$700 million valuation the do seem to have a bit more . . . traction than Vaxil.

Maybe if clinical trials on the horizon for Vaxil that'll help close the valuation gap.

https://vaxil-bio.com/vaxil-appoints-a-special-advisor-to-the-board-of-directors/

Hopefully it won't tank too far if the news doesn't meet expectations. Vaxart being an example. When their news had one negative outcome among many good it tanked somewhat.

Well, it’s looking like next week we will all find out if this thing goes way up, or way down! GL

Totally agree. I was late in the game. Been buying since .34.

I’m trying to accumulate ASAP as well. Time is running out. Good to accumulate at these prices (or less of course).

I'm seeing this as very much in its infancy stages. I am in the process of accumulating a fairly significant position. If the challenge proves successful I'm seeing 5 bucks near term. Depending on how they raise money on the next round will be very telling. I've learned that the science is potentially ground breaking.

I agree. Expecting it any moment. Shouldn't be much of a process to compile results at this point. Probably why volume is picking up.

@Sociocobb, you say it’s a “millionaire maker”. What stock price/ how high do you envision Vaxil (potentially) going? Could they also become a buyout candidate by Big Pharma? What are your thoughts (in your opinion)? Thank you.

PR this week? The mice were challenged and all is well? Could get a big pop soon. We shall know very soon!

Gary. Vaxil is a millionaire maker. I've got some info from our Israeli site (I know...sounds familiar) that the technology is squared the F away. I'm in the process of accumulating 30k shares. The longer this thing bounces around here the better. Still in its infancy stage. Love this company.

Good luck, I hope you're right. I know several people who've invested in CVM and generally they feel as you do. I've just seen them burn so many people in the past that I wouldn't touch them again.

Vaxil was something I heard about and liked what I saw. I feel it's very early in the companies growth, no telling how far it can go.

Gary

Shhhhhh...

I appreciate it Gary. But I've got a line on some info regarding a certain solid tumor biomarker that was identified in P2 and has been leaked from the Israeli site in P3 that Multikine is nearly 100% effective on. Mathematically speaking, OS should come in around 18% but more importantly several of the secondary endpoints will SHINE. The trail design is such that the secondary endpoints alone should garner approval.

I'd be cautious about Multikine, it's been in trials for all sorts of disease for decades and failed in the end. I invested decades ago when it was touted as the answer to AIDS, then the symbol was HIV.

I'm heavily into NWBO and believe that the DCVax's could prove to be a part of the treatment of most solid cancers by the end of this decade.

Gary

I agree. Several key points involving the animal challenge data. 1.As mutated strains of the virus continue to take hold, the world will begin to understand the importance of signal peptides. 2. Our technology is focused on this. 3. The team behind it are some of the brightest and most innovative in the world. 4. The conservative approach to PR lends credibility to the company and the CEO... I'm building a significant position here trying to time the daily lows. Why daily? Because an update can come out at any minute and I'm anticipating stellar results. Do not underestimate Israeli innovation.

For the record I am also long Lorenlimab, DCVax-L, and Multikine. I have a history of picking multi-baggers through deep DD and intuition. This one's a winner. If you're not accumulating, tuck this one away as daily flux in the share price has nothing to do with success or failure.

Finally going up love that no more cheapies.

Vaxil wil be successful where Vaxart failed! We have the signal peptides and they have sh!t going to 10 bucks like them.

Hope for green today and next week news about the mice. Let's roll.

New video out!

Vaxil Bio; Welcoming Dr Michael Berelowitz to the Board, answering more Investors Questions

Come on bring the news finally. This will fly in a minute.

Let's go and push this to new highs! Join our VXLLF Group:

https://discord.gg/NUwEXr5z9Q

Let's push this to 0,50 today at least. News will come and push it even higher!

The discord group for vxllf is active this week, so if you like that sort of thing they are trying to get to 2000 users (for vxl/vxllf) today. show your support by signing up.

https://discord.gg/yCXArgsF

This will fly!!!


https://www.youtube.com/channel/UC0M029aN8g6beW09Drgt0dQ

To the moon, baby!

https://cdn-ceo-ca.s3.amazonaws.com/1g1gum9-Vaxil%20Bio%20Timeline%20_%20DD.pdf

FURTHER UPDATE ON USAMRIID CHALLENGE AND ADDITIONAL EUROPEAN PATENT GRANTED FOR VAXIL’S ANTICANCER ANTIBODY PLATFORM


NESS-ZIONA, Israel, Feb. 01, 2021 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that Dr. Michael Berelowitz has been appointed as special advisor to its board.

Dr. Michael Berelowitz, formerly Pfizer’s Head of Clinical Development and Medical Affairs (Specialty Care), has enjoyed a 50+ year career in the biomedical sciences across the clinical practice of medicine, basic and clinical research and teaching, along with senior responsibilities in administration, budget management, and people leadership in academia and pharmaceutical companies/industry settings. Michael has also served on company boards, including public companies. This diverse experience provides Michael with a unique and valuable understanding of the world's biopharmaceuticals and their future. Dr. Berelowitz’s full bio is detailed below.

Dr. Berelowitz has been granted 125,000 stock options (the "Options") pursuant to the Company's stock option plan, exercisable into an equal amount of common shares in the capital of the Company (“Common Shares”) at an exercise price of CAD $0.42 per Common Share. The Options vest in four equal installments, with the first installment on March 31, 2021, and the subsequent installments on June 30, 2021, September 30, 2021 and December 31, 2021 respectively. All the Options expire on February 1, 2026.

The company further updates that the USAMRIID experiment is proceeding on schedule, including the COVID-19 challenge, which was administered late last week.

The Company further advises that it has successfully obtained a European patent for its anticancer antibody platform - European Patent EP2756307B1 entitled “Antibodies directed against signal peptides, methods and uses thereof”. This granted patent provides broad patent protection for an antibody for use in the treatment of a MUC1 expressing cancer, as well as for an ex vivo method of diagnosing cancer in a subject and an ex vivo method for determining the suitability for treatment of a subject suffering from a MUC1 expressing cancer. Kits for practicing these methods are also included. This patent strengthens Vaxil Bio’s broad patent coverage with regards to its proprietary anti-cancer and anti-pathogenic portfolio.

“We are very pleased to welcome Michael as a special advisor to our board. His extensive and relevant experience will significantly add to our talented team of executives and scientists. I am excited to be able to bring his medical background together with business acumen to support our portfolio and future growth as we progress through preclinical and future clinical phases,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “the granting of an additional European patent bolsters our already robust patent portfolio and demonstrates our commitment to further expand our pipeline across oncology and infectious diseases.”

Vaxil Provides Update on USAMRIID, Oral Experiment and Other General Business Matters.

https://ca.finance.yahoo.com/news/vaxil-provides-usamriid-oral-experiment-125000357.html

I don't think the idea is to not get the second dose, but rather that it might be a few weeks later till it is available. In a few weeks I hope 1 or 2 more vaccines will be available including J&J which is supposed to be a one shot vaccine.

If the NY Times article is based on verifiable data, then it's really reassuring as I was concerned about that 5%.

There does not appear to be a consensus by the medical profession as to whether or not the strategy of vaccinating as many people as possible without the certainty of being able to administer a second dose is a good strategy. I'm not sure of the "50% effective, 50% mild cases" theory. I would not want to take any chances.

In my view all front line workers and others at high risk should get both doses as recommended. As for the rest they need to get their act together and start ramping up distribution, production, and increasing the number of facilities that can administer the vaccine. Fortunately for Americans tomorrow brings the promise of better days ahead.

Bruce,

I know little about their production capability. The question is, if they move the vaccine into people, and if it's determined to be effective, do they have the capability to generate millions, or tens of millions, or hundreds of millions of doses annually.

As I see it, worldwide the need for Covid-19 vaccines is great. A friend sent me a NY Times article indicating that in reality th e vaccines currently in use are really close to 100% effective, not because you won't get Covid-19 with them, but rather for the 5% that does, it's a mild case.

Even if a vaccine were 50% effective, if the other 50% had mild cases, the threat would be greatly diminished. What I don't know is if on a single dose which is said to be about 50% effective, does the other 50% only get mild cases of the disease. If that were the case, I would think it better to get all that first dose even if it meant the second didn't come for a few months.

Gary

That is not at all unusual. Anytime you read about a preclinical study, no matter the nature of the medical research, it it is done on animals and takes place before any testing in humans is done.

Testing on Mice ? Not sure how they can tell if a vaccine works on mice, and how does that mean it works on people ?
Then will they still have to put it through the Phase 1,2,3 testing on people ?

Mice being vaccinated two weeks shiv and tested by exposure to Covid this mid January by USARMY

Anyone know what's going on today. I suspect someone knows something.

Gary

I purchased it at Milo's suggestion as well, I've not sold a share, though I don't have that big a position. If the company maintains it's current price, I suspect it will be able to move off the grey market and onto the OTC, then it will be much more visible. When Milo suggested it, he advised purchasing it as VXL on the Canadian exchange, but I purchase VXLLF through Fidelity, who assured me it was precisely the same when you convert from Canadian currency to U.S.

I believe that most of the work they do is done in Israel, I'm uncertain why they choose to put it on the Canadian exchange. I did just look it up and the site I was taken to by Fidelity for a detailed quote indicated that it's on the OTC. I'm uncertain if that's right, or if Grey quotes as OTC. I would have thought the symbol would change if moved to the OTC from the Grey's.

I saw one report indicating they intend to release further results late January, it didn't specify which product. I'm uncertain if it's Covid related, but clearly they have something which may work on Covid in addition to what they originally intended it for. The company is also working on MM and other cancers, no telling what's really working for them. I'm planning to let it ride. By far my biggest investment is in NWBO which I believe has explosive potential once they release the TLD from their Phase 3 Trial.

Hope you have a great year as well, stay healthy.

Gary

Yes that is the news that has created such excitement. The link contains the following info posted by the CEO David Goren. The "$1.3 million cash and cash equivalents" is more than the cash that I thought they had, but then again I don't know what the "equivalents" refers to.

This stock was recommended to me by MjMilo and bought a bunch over a year ago. Fortunately I kept a few. Still puzzled why it hasn't received more attention on this board. But maybe that's a good thing!

GLTY. I hope you have a great year!

VAXIL’S ANNUAL AND SPECIAL SHAREHOLDERS MEETING AND UPDATE ON EXERCISE OF WARRANTS
Posted on January 2, 2021 by David Goren
02
JAN
Not for distribution by US newswire or in United States

NESS-ZIONA, ISRAEL – December 31, 2020 – VAXIL BIO LTD. (“VAXIL” or the “COMPANY”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that at the Company’s Annual and Special General Meeting, held on December 30, 2020 in Toronto, all resolutions were duly passed by shareholders.

The Company also announces that since November 26, 2020, the date of the filing of our condensed consolidated interim financial statements for the nine months ended September 30, 2020, we have received aggregate proceeds of $115,000 from the exercise of previously issued (January 2018) warrants, having an exercise price of $0.10 per warrant.

As of December 30, 2020, the Company has $1.3 million in cash and cash equivalents.